Our CEO Stefan Savić wrote a commentary for Seznam Zprávy, one of the Czech Republic’s leading news outlets, on a problem we see every day: Europe produces excellent science, but too little of it becomes a product that reaches patients.
With the EU Biotech Act on the table, Europe is preparing to put billions into science and biotechnology. Stefan welcomes the effort, especially the push to speed up clinical trials. But he warns that money alone will not solve it. If technology transfer does not work, the best discoveries stay at the level of a publication or a patent, or move to American investors together with the value they create.
The critical gap, he argues, lies between academic research and an investable start-up. A project at this stage must prove that its principle works, protect its intellectual property, show that it answers a real clinical need, prepare a path through regulation, describe how it will be manufactured and assemble a team to lead the development. It is too applied for grants and too risky for traditional venture capital. That is Europe’s “valley of death”.
Stefan also calls for a different way of measuring success. Universities should be judged not by the number of patents alone, but by the technologies they license, the spin-offs they create and the private capital they attract. And a faster clinical trial should mean a measurably shorter time to the first enrolled patient, not just a shorter legal deadline.
His message on clinical trials in Czechia is just as clear. Hosting foreign studies is valuable for hospitals and patients, but the real value of a successful development belongs to whoever owns the intellectual property. The ambition should be for more trials to be run by companies born from Czech and European science.
This is the gap LIFE bioCEEd exists to close: finding promising research early and helping it reach investors, industry and patients.
“We don’t just need more money for science. Above all, we need a more effective bridge between the two.”
The commentary also covers:
· Why the debate on European biotech should ask where in the innovation chain money is available, not only how much
· Why Europe lacks capital in later stages and what that means for the best companies
· How Czech science can systematically prepare its results for technology transfer
Read the full commentary on Seznam Zprávy (in Czech): https://www.seznamzpravy.cz/clanek/ekonomika-ocima-byznysu-ocima-byznysu-ceske-udoli-smrti-mezi-napadem-a-penezi-319090